---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-197751"
form_type: "8-K"
ticker: "DNTH"
cik: "0001690585"
company_name: "Dianthus Therapeutics, Inc. /DE/"
filed_at: "2025-09-08T23:59:59+00:00"
generated_at: "2026-05-17T07:37:45.727142+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Dianthus reports positive Phase 2 MaGic trial for claseprubart in gMG; both doses meet endpoints

## Summary
- Claseprubart 300mg Q2W: MG-ADL mean change -4.6 (placebo-adjusted -1.8, p=0.0113); QMG -4.4 (adj. -2.4, p=0.0144) at Week 13.
- Claseprubart 600mg Q2W: MG-ADL mean change -5.4 (adj. -2.6, p=0.0006); QMG -4.5 (adj. -2.5, p=0.0111).
- Rapid onset: both doses showed stat. significant MG-ADL and QMG improvement as early as Week 1.
- Favorable safety: no related serious infections, SAEs, or discontinuations; no Boxed Warning or REMS anticipated for planned autoinjector.
- Phase 3 gMG trial evaluating 300mg Q2W and Q4W vs placebo planned to start in 2026; CIDP and MMN data expected 2H 2026.

## SEC filing metadata
- accession: 0001193125-25-197751
- form_type: 8-K
- ticker: DNTH
- cik: 0001690585
- company_name: Dianthus Therapeutics, Inc. /DE/
- filed_at: 2025-09-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1690585/000119312525197751/0001193125-25-197751-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1690585/000119312525197751/d933929d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-197751
- JSON: https://secwatch.observer/filing/0001193125-25-197751.json
- Plain text: https://secwatch.observer/filing/0001193125-25-197751.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.